Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- Drug Discovery
- cardiac
- Ophthalmological
- Pharmaceuticals
- Delivery
- Disease
- DNA
- Genome
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 315793
Licensor grants to Licensee an irrevocable Option during the Option Period to obtain an exclusive license from Licensor in the Territory, under Licensor Patent Rights and Licensor Know-how, to develop, make, have made, use, sell, offer to sell and import, Licensed Products containing Compounds which are VEGF Material.
5,580,859 – Delivery of exogenous DNA sequences in a mammal
5,589,466 – Induction of a protective immune response in a mammal by injecting a DNA sequence
Licensed Product means preparations in final form for sale by prescription, over the counter or any other method for all uses, in humans which contain Compound, including, without limitation, any combination product.
Compound means FGF Material.
FGF Material means plasmid constructs of fibroblast growth factors (FGF), including FGF-1 (aFGF), coding all alleles, alternatively spliced isoforms, mutants and forms containing artificial secretory leader sequences that have among their biologic activities angiogenic and/or vascular endothelial cell mitogenic activity. FGF Material encompasses FGF-1 through FGF-12 and homologous family members including any FGF homologues that are or will be identified with at least 62% sequence homology and that have among their.biologic activities angiogenic and/or vascular endothelial cell mitogenic activity.
Option means the option to obtain rights under Licensor Patent Rights with respect to VEGF Material.
Licensor is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases including methods for the administration of plasmid DNA to humans, which DNA expresses physiologically active proteins for human therapeutic applications.
Licensee is a premier research-intensive biopharmaceutical company researching to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases, such as HIV and Ebola, and emerging animal diseases.
IPSCIO Record ID: 233425
Injection Catheter means the injection catheter known as the Stilettoâ„¢ manufactured by Licensor, including improvements, modifications and replacements thereto.
Product means a plasmid DNA, drug, biologic or other composition comprising VEGF-2. Product does not include any delivery device, including without limitation the Injection Catheter, a hypodermic needle or stent, or the combination of any such plasmid DNA, drug, biologic or other composition with any such delivery device.
VEGF-2 means the Human Genome Sciences angiogenic agent licensed to and being further developed and modified by the Company, sometimes referred to as Vascular Endothelial Growth Factor 2 plasmid DNA, and any modifications or improvements thereto.
IPSCIO Record ID: 311
ZALTRAP is an FDA-approved anti-cancer medicine given in combination with a chemotherapy regimen called FOLFIRI (foal-feer-ee) to treat colorectal cancer that has spread.
IP relates to the Davis-Smyth patents, and certain other patents, in all indications for human use other than the prevention or treatment of eye diseases and eye disorders through administration to the eye. Under the terms of the ZALTRAP Agreement, payments are required to be made to licensor based on sales of ZALTRAP in the United States and of ZALTRAP that is manufactured in the United States and sold outside the United States through May 7, 2016.
The partner commenced sales of ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan ('FOLFIRI'), for patients with metastatic colorectal cancer (“mCRCâ€) that is resistant to or has progressed following an oxaliplatin-containing regimen, in the United States in the third quarter of 2012 and in certain European and other countries in the first quarter of 2013.
The licensee and partner globally collaborate on the development and commercialization of ZALTRAP.
Licensed Patents
.S. Patent No. 5,952,199
U.S. Patent No. 6,100,071
U.S. Patent No. 6,383,486
U.S. Patent No. 6,897,294
U.S. Patent No. 7,771,721
U.S. Patent No. 8,268,313
U.S. Patent No. 8,268,591
U.S. Patent No. 8,273,353
U.S. Patent Application No. 08/643,839
U.S. Patent No. 7,998,931
U.S. Patent No. 8,007,799
U.S. Patent No. 8,287,873
U.S. Patent Application No. 12/002,605
IPSCIO Record ID: 203979
Licensor grants non-exclusive, non-transferable options to obtain licenses for up to three (3) Licensee identified Research Genes exercisable during the research term of this Agreement.
With respect to exclusive Licensee products directed to a Licensee research gene for which Licensee has exercised an option Licensor is obligated to grant a license. Licensor grants to Licensee an exclusive worldwide license under Licensor technology and patents to research, develop, make, have made, use, import, export, offer to sell and sell such exclusive Licensee products in the field.
